SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C-144-01 stud ...

Core Viewpoint - Iovance Biotherapeutics has an approved drug, Amtagvi, for treating unresectable or metastatic melanoma, but its stock has significantly declined, raising concerns among investors about its future performance [1][2]. Group 1: Stock Performance and Market Sentiment - Iovance's stock has fallen approximately 57% since the beginning of the year as of April 22, indicating a significant sell-off [5]. - The percentage of short-sellers in relation to Iovance's float has been increasing, reflecting growing skepticism about the company's future success [3]. Group 2: Financial Health and Cash Flow - Iovance is experiencing poor cash flow, which may lead to further dilution for shareholders as the company has historically relied on issuing stock to fund operations [11]. - As of the end of 2024, Iovance had cash and short-term investments totaling $323.8 million, but ongoing high cash burn could deplete this cushion over time [10]. Group 3: Future Revenue Potential - Although Amtagvi has the potential to generate $1 billion in annual revenue, this is not expected until 2030, which raises concerns about the company's ability to achieve profitability in the near term [7][12]. - Iovance reported a net loss of $372.2 million last year, highlighting the financial challenges it faces [12].

Some investors see a striking similarity between lottery tickets and biotech stocks. In most cases, buying lottery tickets ends up being a waste of money. So does investing in most biotech stocks. But just as one lucky lottery ticket can provide game-changing wealth, so can the right biotech stock.Iovance Biotherapeutics (IOVA 0.30%) just might be the right kind of biotech stock. The company has already achieved success. Could it even be a millionaire-maker?Iovance's opportunityTo appreciate Iovance's oppor ...

Core Viewpoint - Iovance Biotherapeutics has innovative cancer therapies but faces challenges in market performance despite regulatory approval of its key therapy, Amtagvi [1][2]. Company Overview - Iovance Biotherapeutics specializes in developing therapies using tumor-infiltrating lymphocytes (TILs) to target cancer cells [3]. - The company’s flagship product, Amtagvi, is a personalized treatment for melanoma that received FDA approval last year [3][4]. Market Performance - The stock has declined by 74% over the past 12 months, trading under $4 per share, which is close to its 52-week low [2]. - Analysts have a bullish outlook, with price targets ranging from $6 to $32, and an average target of $19.54 [2]. Product Details - Amtagvi takes 34 days to manufacture and is administered in specialized treatment centers, which complicates its rollout [4]. - Iovance reported $164.1 million in revenue last year and has only begun to address the 20,000 eligible melanoma patients in the U.S. [5]. Market Potential - There are an estimated 325,000 annual melanoma cases worldwide, indicating a significant market opportunity for Iovance [6]. - The company is seeking regulatory approvals in additional countries, potentially expanding its patient base by 2025 [5][8]. Future Projections - Iovance anticipates product revenue for Amtagvi to be between $450 million and $475 million in 2025 [9]. - The company has a pipeline of over a dozen programs, including trials for non-small cell lung cancer, which could serve as catalysts for growth [10]. Financial Outlook - Iovance aims to keep its cash burn under $300 million for 2025, which is below its projected revenue range [11]. - The company improved its net loss per share from $1.89 in 2023 to $1.28 in 2024, indicating progress in financial performance [12].

The time to buy quality prospects is when the rest of the market is ignoring their value.Most investors know the market's down quite a bit from February's high. Not all investors realize that a handful of compelling stocks were already sliding before the marketwide correction started, and that several of these same names haven't yet even hinted at a recovery. Wall Street's seemingly given up on them, looking right past everything that makes these companies -- and their stocks -- so promising.Not me, though. ...

When a stock is in a freefall, there's usually a justifiable reason for the decline. But for investors with a high risk tolerance, it could make for a potentially attractive contrarian play. A stock that has fallen to a fraction of its price could possess significant upside if it's able to prove its doubters wrong.One stock that's down big of late is Iovance Biotherapeutics (IOVA -1.28%). Entering trading this week, the healthcare stock has lost close to 60% of its value in the past three months, and it's d ...

Iovance Biotherapeutics (IOVA) Q4 2024 Earnings Call March 01, 2025 01:56 AM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporate CommunicationsFrederick Vogt - Interim CEO, President, General Counsel & Corporate SecretaryDan Kirby - Chief Commercial OfficerIgor Bilinsky - Chief Operating OfficerJean-Marc Bellemin - Chief Financial OfficerFriedrich Graf Finckenstein - Chief Medical OfficerAndrea Newkirk - Biotechnolgy Equity ResearchBenjamin Burnett - DirectorNic ...

After working as a Registered Nurse for several years, I transitioned into financial analysis, earning my MBA and developing expertise in healthcare & technology investments. Since 2017, I've published investment analyses on Seeking Alpha, focusing on thorough valuation modeling. My approach centers on examining core assumptions that drive stock valuations, particularly through detailed discounted cash flow analysis. I provide readers with various scenarios to help them understand potential outcomes. The pr ...

Core Insights - Iovance Biotherapeutics reported a narrower loss of 26 cents per share for Q4 2024, compared to a loss of 45 cents per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 27 cents [1][7] - The company generated total revenues of $73.7 million in Q4 2024, significantly up from $0.5 million in the year-ago quarter, and exceeding the Zacks Consensus Estimate of $72.1 million [2][7] Revenue Breakdown - Iovance's revenue for Q4 2024 was driven by sales from two marketed drugs: Proleukin and Amtagvi [3] - Amtagvi sales reached $48.7 million in Q4 2024, up from $42.1 million in Q3 2024, although it fell short of the model estimate of $57 million [4] - Proleukin contributed $25 million in sales during the quarter, a significant increase from $0.5 million in the year-ago period, surpassing the model estimate of $15 million [5] Operating Costs - Research and development expenses decreased by 17% to $72.2 million compared to the previous year, attributed to the transition to commercial manufacturing of Amtagvi [6] - Selling, general, and administrative expenses increased by 42% to $42.5 million, driven by higher headcount and related costs [6] Full-Year Performance - For the full year 2024, Iovance reported total revenues of $164.1 million, a substantial increase from $1.2 million in the previous year [7] - The company incurred a loss of $1.28 per share for 2024, an improvement from a loss of $1.89 per share in the prior year [7] Future Guidance - Iovance reiterated its revenue guidance for 2025, expecting product revenues to be between $450 million and $475 million, with cash burn projected to be under $300 million [8] - The company anticipates significant growth in total product revenues for 2026 and beyond, with gross margins expected to exceed 70% in the coming years [9] Pipeline Updates - Regulatory applications for Amtagvi in melanoma are under review in the EU, UK, and Canada, with potential approvals expected this year [13] - Iovance is conducting a phase III study evaluating Amtagvi combined with Merck's Keytruda for frontline advanced melanoma [14] - The company is also accelerating enrollment in a phase II study for Amtagvi in post-anti-PD-1 non-small cell lung cancer, with updates expected by year-end [15]

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.70%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.31 per share when it actually produced a loss of $0.28, delivering a surprise of 9.68%.Over the last four quarters, the ...